Published in Rheumatology (Oxford) on September 01, 2000
Nitric oxide and bone. Immunology (2001) 1.60
Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther (2008) 1.28
Interleukin-1beta induces death in chondrocyte-like ATDC5 cells through mitochondrial dysfunction and energy depletion in a reactive nitrogen and oxygen species-dependent manner. Biochem J (2005) 1.00
Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis (2003) 0.92
Synovial fluid nitric oxide levels in patients with knee osteoarthritis. Clin Rheumatol (2003) 0.90
Calreticulin promotes angiogenesis via activating nitric oxide signalling pathway in rheumatoid arthritis. Clin Exp Immunol (2014) 0.85
Effect and mechanism of AR-6 in experimental rheumatoid arthritis. Clin Exp Med (2009) 0.82
Polymorphisms of the eNOS gene are associated with disease activity in rheumatoid arthritis. Rheumatol Int (2015) 0.82
Molecular basis of oxidative stress in gouty arthropathy. Clin Rheumatol (2015) 0.77
Inhibition of Inducible Nitric Oxide Synthase Attenuates Monosodium Urate-induced Inflammation in Mice. Korean J Physiol Pharmacol (2011) 0.77
Monosodium urate crystals induce oxidative stress in human synoviocytes. Arthritis Res Ther (2016) 0.75
Reply. J Hypertens (2015) 0.75
Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis. Int J Nanomedicine (2017) 0.75
Associations between eNOS polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis. Z Rheumatol (2016) 0.75
Mineralisation defects with pamidronate therapy for Paget's disease. Lancet (1993) 2.76
Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med (1998) 2.64
Management of Paget's disease of bone. Rheumatology (Oxford) (2004) 2.60
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Guidelines on the management of Paget's disease of bone. Bone (2002) 2.34
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet (1996) 2.23
Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet (1985) 2.15
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet (2000) 2.13
A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest (2001) 1.98
Association of polymorphism at the type I collagen (COL1A1) locus with reduced bone mineral density, increased fracture risk, and increased collagen turnover. Arthritis Rheum (1999) 1.70
Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res (2000) 1.70
Nitric oxide and bone. Immunology (2001) 1.60
Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res (1991) 1.57
Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis (2010) 1.53
Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Br Med J (Clin Res Ed) (1986) 1.47
Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. Bone (2003) 1.44
A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene (2000) 1.43
Hypercalcaemia of malignancy: evidence for a nonparathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci (Lond) (1984) 1.36
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis (1995) 1.34
Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology (2001) 1.32
Detection of nitric oxide and nitric oxide synthases in psoriasis. Arch Dermatol Res (1998) 1.25
Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol (2000) 1.18
Vitamin D receptor polymorphism, bone mineral density, and osteoporotic vertebral fracture: studies in a UK population. Bone (1996) 1.14
Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet (2001) 1.14
Collagen Ialpha1 Sp1 polymorphism, bone mass, and bone turnover in healthy French premenopausal women: the OFELY study. J Bone Miner Res (1998) 1.13
Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol (1993) 1.13
Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism. J Immunol (1997) 1.09
Polymorphisms of the interleukin-6 gene are associated with bone mineral density. Bone (1997) 1.08
Nitric oxide response to shear stress by human bone cell cultures is endothelial nitric oxide synthase dependent. Biochem Biophys Res Commun (1998) 1.08
Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. J Med Genet (2005) 1.08
Bone mineral density, collagen type 1 alpha 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia (1998) 1.08
Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum (2001) 1.07
A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res (2000) 1.07
Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) (1984) 1.05
Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone (2001) 1.05
An Sp1 binding site polymorphism in the COLIA1 gene predicts osteoporotic fractures in both men and women. J Bone Miner Res (1998) 1.04
Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone (2000) 1.04
Too much heparin: possible source of error in blood gas analysis. Br Med J (Clin Res Ed) (1983) 1.02
Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res (1998) 1.02
Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy. Bone Miner (1991) 1.02
Origin of a negative calcium response element in an ALU-repeat: implications for regulation of gene expression by extracellular calcium. Bone (1995) 1.01
Clinical experience with pamidronate in the treatment of Paget's disease of bone. Ann Rheum Dis (1991) 1.01
Cross-calibration of dual-energy X-ray densitometers for a large, multi-center genetic study of osteoporosis. Osteoporos Int (2005) 1.00
Intrapulmonary epinephrine during prolonged cardiopulmonary resuscitation: improved regional blood flow and resuscitation in dogs. Ann Emerg Med (1984) 1.00
Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res (1997) 1.00
Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int (2007) 1.00
Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol (1997) 0.99
Side-effects of pamidronate. Lancet (1989) 0.98
Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc Natl Acad Sci U S A (2000) 0.98
Presentation and management of osteoporosis presenting in association with pregnancy or lactation. Osteoporos Int (2015) 0.98
Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res (1999) 0.97
Elevated nitric oxide production in rheumatoid arthritis. Detection using the fasting urinary nitrate:creatinine ratio. Arthritis Rheum (1996) 0.97
Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology (1998) 0.97
Expression of nitric oxide synthase isoforms in bone and bone cell cultures. J Bone Miner Res (1997) 0.96
Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone (1996) 0.96
Relationship between physical activity and bone mineral status in young adults: the Northern Ireland Young Hearts Project. Bone (2002) 0.95
Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. Calcif Tissue Int (2001) 0.95
Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol (1995) 0.94
Association between COLIA1 Sp1 alleles and femoral neck geometry. Calcif Tissue Int (2001) 0.94
Estrogen receptor alpha gene polymorphisms and bone mineral density: haplotype analysis in women from the United Kingdom. J Bone Miner Res (2001) 0.94
clinical risk factors for osteoporosis in Ireland and the UK: a comparison of FRAX and QFractureScores. Calcif Tissue Int (2011) 0.94
Type II benign osteopetrosis (Albers-Schönberg disease) caused by a novel mutation in CLCN7 presenting with unusual clinical manifestations. Calcif Tissue Int (2003) 0.93
Lack of association between the SOST gene and bone mineral density in perimenopausal women: analysis of five polymorphisms. Bone (2002) 0.93
Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis (1994) 0.92
Susceptibility to osteoporotic fracture is determined by allelic variation at the Sp1 site, rather than other polymorphic sites at the COL1A1 locus. Osteoporos Int (2000) 0.92
Methylenetetrahydrofolate reductase polymorphism interacts with riboflavin intake to influence bone mineral density. Bone (2004) 0.92
Localisation of the gene causing diaphyseal dysplasia Camurati-Engelmann to chromosome 19q13. J Med Genet (2000) 0.92
Association of COLIA1 Sp1 alleles with defective bone nodule formation in vitro and abnormal bone mineralization in vivo. Calcif Tissue Int (2005) 0.91
Bisphosphonates prevent the hungry bone syndrome. Nephron (1996) 0.90
Polymorphisms in the 5' flank of COL1A1 gene and osteoporosis: meta-analysis of published studies. Osteoporos Int (2010) 0.90
Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif Tissue Int (2006) 0.90
Nitric oxide and bone. J Bone Miner Res (1996) 0.90
Structural and functional studies of mutations affecting the UBA domain of SQSTM1 (p62) which cause Paget's disease of bone. Biochem Soc Trans (2004) 0.89
Control genes for reverse-transcription-polymerase chain reaction: a comparison of beta actin and glyceraldehyde phosphate dehydrogenase. Br J Haematol (1997) 0.89
Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells. Bone (1999) 0.89
Nitric oxide production in cells derived from the human joint. Br J Rheumatol (1996) 0.89
Presentation of a PTHrP-secreting pancreatic neuroendocrine tumour, with hypercalcaemic crisis, pre-eclampsia, and renal failure. Postgrad Med J (2002) 0.89
Breast cancer-associated hypercalcaemia: a reassessment of renal calcium and phosphate handling. Ann Clin Biochem (1990) 0.88
Lack of influence of collagen type Ialpha1 Sp1 binding site polymorphism on the rate of bone loss in a cohort of postmenopausal danish women followed for 18 years. Calcif Tissue Int (2000) 0.88
p62 mutations, ubiquitin recognition and Paget's disease of bone. Biochem Soc Trans (2006) 0.87
The effect of nutrient intake on bone mineral status in young adults: the Northern Ireland young hearts project. Calcif Tissue Int (2002) 0.87
Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bone. J Bone Miner Res (1994) 0.87
Cytokine-activated endothelium recruits osteoclast precursors. Endocrinology (2001) 0.87
COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss. J Bone Miner Res (2001) 0.87
COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int (2002) 0.86
Studies of bone density, quantitative ultrasound, and vertebral fractures in relation to collagen type I alpha 1 alleles in elderly women. Calcif Tissue Int (2001) 0.86
Prediction of osteoporotic fractures by bone densitometry and COLIA1 genotyping: a prospective, population-based study in men and women. Osteoporos Int (2001) 0.85
Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2008) 0.84
Polymorphism of the collagen type Ialpha1 gene and ethnic differences in hip-fracture rates. N Engl J Med (1998) 0.84
Cardiac, thoracic, and abdominal pump mechanisms in cardiopulmonary resuscitation: studies in an electrical model of the circulation. Am J Emerg Med (1984) 0.84
Effect of a COL1A1 Sp1 binding site polymorphism on arterial pulse wave velocity: an index of compliance. Hypertension (2001) 0.84
Cardiopulmonary resuscitation with interposed abdominal compression in dogs. Anesth Analg (1982) 0.83
Cytokine expression in multiple myeloma and monoclonal gammopathy: analysis by reverse transcription/polymerase chain reaction and quantitative PCR. Leuk Lymphoma (1996) 0.83
Circulating vitamin D metabolites and hypercalcaemia of malignancy. Acta Endocrinol (Copenh) (1984) 0.83
Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? QJM (2001) 0.83
Role of genetic factors in the pathophysiology and management of osteoporosis. Clin Endocrinol (Oxf) (2001) 0.82
Diagnosis and management of primary hyperparathyroidism in Europe. QJM (2012) 0.81